SCHEMBL6422704

SCHEMBL6422704

CCOC(=O)c1nc2c(N)nc(SC)nc2[nH]c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 4/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
RECQL P46063 1/20 0.40
CYP1A2 P05177 1/20 0.37
MAPT P10636 3/20 0.37
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6382922 0.79 KDM4E (0.43) LMNAKDM4EALDH1A1HPGDHTT
SCHEMBL3857600 0.77 CXCR2 (0.61) LMNAALDH1A1HPGDMAPT
SCHEMBL29478346 0.72 LMNA (0.49) LMNAKDM4EALDH1A1HPGDHTT
SCHEMBL5228038 0.72 LMNA (0.49) LMNAKDM4EALDH1A1HPGDHTT
SCHEMBL31289711 0.71 POLB (0.50) LMNAKDM4EALDH1A1CYP1A2MAPT
SCHEMBL5435124 0.71 CXCR2 (0.49) LMNAKDM4EALDH1A1HPGDHTT
SCHEMBL13314715 0.69 MEN1 (0.54) KDM4EALDH1A1CYP1A2MAPTMAPK1
SCHEMBL7849089 0.69 KDM4E (0.58) LMNAKDM4EALDH1A1HPGDHTT
SCHEMBL22573664 0.67 KDM4E (0.49) LMNAKDM4EALDH1A1HPGDHTT
SCHEMBL2843820 0.67 ALDH1A1 (0.59) LMNAKDM4EALDH1A1HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501850-A2 NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION GENELABS TECHNOLOGIES, INC. (US) 2005-02-02 EP disclosed
US-20040063658-A1 Nucleoside derivatives for treating hepatitis C virus infection GENELABS TECHNOLOGIES, INC. 2004-04-01 US disclosed
WO-2003093290-A2 NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION GENELABS TECHNOLOGIES, INC. (US) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063658-A1 Nucleoside derivatives for treating hepatitis C virus infection HAVCR2, PNP, NTPCR LMNA 1900/4885KDM4E 4438/4885ALDH1A1 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.